Added Decitabine to the list. The US breast cancer sales in combo with Dox are estimated to be $1.7b p.a. USD + AML (ORANGE). Now extrapolate with the planned AML and allcomers trial (YELLOW) / geographical license deals. Note - Other documented Synergies (LIGHT ORANGE). Untapped opportunities (ICEBERG WHITE).
Now, add the latest Decitabine Synergies and opportunity with Astex/Otsuka (GREEN). Also, it hasn't previously been mentioned but look at the Astex partnership, could be a backdoor to Big BP deals down the track.
Ann: Bisantrene with Decitabine Enhances Cancer Cell Killing, page-101
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
-0.060(3.77%) |
Mkt cap ! $260.7M | |||
| Open | High | Low | Value | Volume |
| $1.59 | $1.59 | $1.53 | $83.43K | 53.65K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20575 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 300 | 1 |
View Market Depth
| Last trade - 16.10pm 16/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |